Menu
Menu
Tafalgie Therapeutics, Research contributing to health and well-being:
innovative polypeptides for the prevention and treatment of pain.
Development of an innovative therapeutic solution for chronic pain
Tafalgie Therapeutics is a simplified joint-stock biotechnology company, spin-off of the IBDM laboratory (AMU/CNRS). The society was created in october 2020 by five founders having complementary and internationally recognized expertise in the fields of neurosciences, research, finance and industrial development.
The goal is to provide innovative solutions for the treatment of post-operative and neuropathic pain.
The company relies on scientific works carried out by Dr. Aziz Moqrich’s team that have highlighted a protein involved in molecular and cellular mechanisms of chronic and acute pain : the TAFA4 protein
Project chronology and history
Tafalgie Therapeutics capitalizes on more than ten years of promising French scientific work.
APPROCH AND context
Tafalgie Therapeutics proposes an innovative and effective drug based on an endogenous protein able to modulate the transmission of pain information to the brain.
Global urgency to develop new antalgics
0
Millions
surgeries are performed each year.
0
%
patients
date undergo surgery are affected.
0
Millions
people in Europe are suffering from chronic pain.
0
%
chronic pain
patients do not receive appropriate treatment for their pain
OUR TEAM
Tafalgie Therapeutics gathers around its management team and founding partners, a Scientific Committee and a Supervisory Board
Founders
Eric Schettini
President
Stephane Gaillard
General Manager
Aziz Moqrich
Chief Strategy Office
Olivier Blin
President of the
Executive Committee
Laurent Labatut
Chairman on the board
Scientific Board
Alain Escalier
Jean-louis Kraus
John Levine
« Pain is considered to be the cause of almost 2/3 of medical consultations. For this reason, it is the subject of numerous studies, both fundamental and clinical.
Active researches on this thematic ARE essential for a better understanding of the mechanisms involved in pain and for the development of new treatments ».
Site Inserm
Contact us
- communication@tafalgie.fr
-
Registered office :
4 avenue Général Grossetti, 13007 Marseille - @tafalgie
Pages
Menu
Tafalgie Therapeutics
Tafalgie Therapeutics is a simplified joint-stock biotechnology company, Spin-off of the IBDM laboratory (AMU/CNRS).
The society is created in october 2020 by five founders having complementary and internationally recognized expertise in the fields of neurosciences, research, finances and industrial development.